Coya Therapeutics GAAP EPS of -$0.45 misses by $0.11, revenue of $0.23M beats by $0.15M

Coya Therapeutics reported 3Q 2026 revenue of $234.13K, down 93.4% YoY, and a net loss of $10.62M, up 401.8% YoY. The decline was due to lower collaboration revenue and higher R&D spending. The company completed enrollment for its COYA 302 ALS Phase 2/3 trial and received FDA Fast Track Designation. Coya expects its cash to last into 2H 2027.

Coya Therapeutics, Inc. (COYA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Coya Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Corporate Update HOUSTON--(BUSINESS WIRE)-- Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance

Coya Therapeutics completed enrollment for its 137-patient ALS trial, ALSTARS, with topline data expected in early Q2 2027. The company reported a Q3 net loss of $10.6M and $35.8M in cash as of September 30, 2026, expected to fund operations into H2 2027. According to Coya, the next major catalyst is the trial readout.

Coya plans to start an open-label extension of its Phase 2/3 ALSTARS trial for COYA 302 in November 2026, delaying its FTD trial to 2027. The company expects its cash runway to extend into the second half of 2027, according to its SEC filing.

H.C. Wainwright reiterated a Buy rating on Coya Therapeutics (COYA) with a $18.00 price target, citing full enrollment in its Phase 2/3 ALSTARS trial for ALS treatment. The stock trades at $4.85, suggesting over 270% upside. The trial aims to evaluate COYA 302's efficacy and safety, with top-line data expected in early Q2 2027. The company holds more cash than debt, providing financial flexibility.

Coya Therapeutics (COYA) announced full enrollment of 120 participants in its Phase 2/3 ALSTARS Trial for ALS treatment. Topline data is expected in early Q2 2027. CEO Arun Swaminathan highlighted the milestone and the potential insights from the trial.